Table 2.
Stimulation of translocations by DNA damaging agents in RAD9 (YB110) and the rad9 :: URA3 diploid (YB134)
| Agent (concentration or dose) | Stimulation in
RAD9 (YB110)a |
Stimulation in
rad9− (YB134)a |
Ratioc | ||
|---|---|---|---|---|---|
| His+/CFU × 107 (survival%) | Netb | His+/CFU × 107 (survival%) | Netb | ||
| Spontaneous | 6 ± 2 | 0 | 23 ± 14 | 0 | NA |
| Alkylating agentsd | |||||
| MMS 0.1% (10.5 (mM)) | 62 ± 16(94) | 59 ± 13 | 248 ± 24(81) | 246 ± 21 | 4.2 |
| MNNG 50 (μM) | 100 ± 9 (88) | 92 ± 1 | 173 ± 46 (90) | 153 ± 38 | 1.7 |
| MNNG 100 (μM) | 250 ± 10 (85) | 248 ± 11 | 347 ± 40 (76) | 326 ± 37 | 1.3 |
| MNNG 200 (μM) | 345 ± 38 (53) | 338 ± 21 | 306 ± 62 (16) | 253 ± 43 | 0.7 |
| Bulky adducts | |||||
| 4-NQO 1 (μM) | 28 ± 9 (100) | 27 ± 14 | 43 ± 6 (100) | 33 ± 10 | 1.2 |
| 4-NQO 10 (μM) | 494 ± 163(67) | 484 ± 160 | 666 ± 91 (47) | 636 ± 96 | 1.3 |
| Cisplatin 1.3 (μM) | 122 ± 33 (100) | 120 ± 25 | 347 ± 71(87) | 330 ± 70 | 2.8 |
| Free radical agents | |||||
| Bleomycin 0.015 units | 60 ± 52 (94) | 54 ± 52 | 446 ± 130(86) | 403 ± 136 | 7.5 |
| Phleomycin 10 (μM) | 67 ± 31(93) | 59 ± 31 | 295 ± 117 (60) | 286 ± 116 | 4.8 |
| H2O2 2 (μM) | 219 ± 92 (76) | 212 ± 92 | 585 ± 259 (76) | 558 ± 260 | 2.6 |
| H2O2 4 (μM) | 346 ± 138(71) | 329 ± 192 | 533 ± 167 (54) | 523 ± 165 | 1.6 |
| TopoI inhibitor | |||||
| Camptothecin 50 (μg/ml) | 5 ± 5 (95) | <1 | 38 ± 14 (99) | 26 ± 14 | 5.2 |
| Camptothecin 100 (μg/ml) | 34 ± 7 (95) | 33 ± 7 | 163 ± 50 (85) | 153 ± 54 | 4.6 |